ArticlePloS one2022
Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Prevalence of Viral Hepatitis in Three Public Health Clinics in the Kingston Metropolitan Area, Jamaica, 2022.The American journal of tropical medicine and hygiene · 2026Article
- The evolution of in vitro culture systems for the study of hepatitis E virus infection.Virology · 2026Review
- Hepatitis E Virus Infection in Patients With Chronic Liver Diseases: A Latin American Multicenter Study.The Journal of infectious diseases · 2026Article
- Trends and projections of hepatitis E incidence in Jiangsu Province of eastern China from 2007 to 2021: An analysis based on age-period-cohort models.Infectious Disease Modelling · 2025Article
- Hepatitis E Virus in the Role of an Emerging Food-Borne Pathogen.Microorganisms · 2025Review
- Meta-analysis of global prevalence of hepatitis E virus infection in deer.Frontiers in microbiology · 2025Article
- Article
- Epidemiology of Viral Hepatitis in the Indigenous Populations of the Arctic Zone of the Republic of Sakha (Yakutia).Microorganisms · 2024Article
- Spatial-temporal analysis of hepatitis E in Hainan Province, China (2013-2022): insights from four major hospitals.Frontiers in public health · 2024Article
- Serological Evidence of Hepatitis E Virus Infection in Brazilian Equines.Microorganisms · 2023Article
- Prevalence, incidence, and outcomes of hepatitis E virus coinfection in patients with chronic hepatitis C.Scientific reports · 2023Article
- Hepatitis E Virus Infections: Epidemiology, Genetic Diversity, and Clinical Considerations.Viruses · 2023Review
- Acute Hepatitis E Infection Associated With Deer Meat in the United States.ACG case reports journal · 2023Article
- [Advances in hepatitis E epidemiology].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Hepatitis E Virus Infection in Patients with Chronic Inflammatory Bowel Disease Treated with Immunosuppressive Therapy.Pathogens (Basel, Switzerland) · 2023Article
- Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from the National Health and Nutrition Examination Survey (NHANES-CDC) to estimate HEV seroprevalence and analyze demographic variables related to the infection. Additionally, we compared 4 serological tests used. The estimated HEV seroprevalence between 2009-2016 was 6.1% (95% CI: 5.6%-7.0%) for IgG and 1.02% (0.8%-1.2%) for IgM. Higher HEV IgG prevalences were found in older people, females, non-Hispanic Asians and those born outside of the U.S. The in-house immunoassay and the Wantai HEV-IgG ELISA presented the highest sensitivity values in the tested population. The highest specificity values corresponded to the DSI-EIA-ANTI-HEV-IgG assay. The kappa statistical values showed concordances no greater than 0.64 between the assays. HEV prevalence in our study was similar to previously reported, and a decline in the prevalence was observed through the NHANES assessments (from 1988 to 2016). The sensitivity and specificity of the assays varied widely, making comparisons difficult and highlighting the need to develop a gold standard assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.